View ValuationAnshan Hifichem 将来の成長Future 基準チェック /06現在、 Anshan Hifichemの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Chemicals 収益成長30.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 24Anshan Hifichem Co., Ltd., Annual General Meeting, May 15, 2026Anshan Hifichem Co., Ltd., Annual General Meeting, May 15, 2026, at 13:00 China Standard Time. Location: No. 8, Yihao Road, Teng'ao Economic Development Zone, Haicheng, Anshan, Liaoning Chinaお知らせ • Mar 31Anshan Hifichem Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026Anshan Hifichem Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026お知らせ • Dec 31Anshan Hifichem Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026Anshan Hifichem Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026お知らせ • Sep 30Anshan Hifichem Co., Ltd. to Report Q3, 2025 Results on Oct 22, 2025Anshan Hifichem Co., Ltd. announced that they will report Q3, 2025 results on Oct 22, 2025お知らせ • Jul 02Anshan Hifichem Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025Anshan Hifichem Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025お知らせ • Apr 18Anshan Hifichem Co., Ltd., Annual General Meeting, May 09, 2025Anshan Hifichem Co., Ltd., Annual General Meeting, May 09, 2025, at 13:00 China Standard Time. Location: No. 8, Yihao Road, Teng'ao Economic Development Zone, Haicheng, Anshan, Liaoning Chinaお知らせ • Mar 31Anshan Hifichem Co., Ltd. to Report Q1, 2025 Results on Apr 18, 2025Anshan Hifichem Co., Ltd. announced that they will report Q1, 2025 results on Apr 18, 2025お知らせ • Dec 31Anshan Hifichem Co., Ltd. to Report Fiscal Year 2024 Results on Apr 18, 2025Anshan Hifichem Co., Ltd. announced that they will report fiscal year 2024 results on Apr 18, 2025Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.021 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.13 (up from CN¥0.021 in 3Q 2023). Revenue: CN¥415.5m (up 31% from 3Q 2023). Net income: CN¥53.0m (up CN¥45.1m from 3Q 2023). Profit margin: 13% (up from 2.5% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 31%After last week's 31% share price gain to CN¥13.06, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 35% over the past year.New Risk • Sep 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.8% average weekly change).お知らせ • Sep 30Anshan Hifichem Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024Anshan Hifichem Co., Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024お知らせ • Sep 21Anshan Hifichem Co., Ltd. Announces 2024 Interim Profit Distribution Plan (A Shares),Payable September 26, 2024Anshan Hifichem Co., Ltd. announced 2024 interim profit distribution plan to be implemented (A shares):Cash dividend/10 shares (tax included): CNY0.50000000. Record date: 25 September 2024, Ex-date: 26 September 2024, Payment date: 26 September 2024.New Risk • Sep 07New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.9% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.Reported Earnings • Aug 27Second quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.007 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.13 (up from CN¥0.007 in 2Q 2023). Revenue: CN¥416.2m (up 35% from 2Q 2023). Net income: CN¥45.6m (up CN¥42.6m from 2Q 2023). Profit margin: 11% (up from 1.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.お知らせ • Jun 29Anshan Hifichem Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024Anshan Hifichem Co., Ltd. announced that they will report first half, 2024 results on Aug 27, 2024Reported Earnings • Apr 16First quarter 2024 earnings released: EPS: CN¥0.05 (vs CN¥0.04 loss in 1Q 2023)First quarter 2024 results: EPS: CN¥0.05 (up from CN¥0.04 loss in 1Q 2023). Revenue: CN¥322.5m (up 22% from 1Q 2023). Net income: CN¥21.6m (up CN¥36.4m from 1Q 2023). Profit margin: 6.7% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China.New Risk • Apr 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Large one-off items impacting financial results.お知らせ • Mar 30Anshan Hifichem Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024Anshan Hifichem Co., Ltd. announced that they will report Q1, 2024 results on Apr 24, 2024お知らせ • Feb 09Anshan Hifichem Co., Ltd., Annual General Meeting, Mar 01, 2024Anshan Hifichem Co., Ltd., Annual General Meeting, Mar 01, 2024, at 13:00 China Standard Time. Location: No. 8, Yihao Road, Teng'ao Economic Development Zone, Haicheng, Anshan, Liaoning ChinaNew Risk • Feb 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Large one-off items impacting financial results.Reported Earnings • Feb 07Full year 2023 earnings released: EPS: CN¥0.03 (vs CN¥0.01 loss in FY 2022)Full year 2023 results: EPS: CN¥0.03 (up from CN¥0.01 loss in FY 2022). Revenue: CN¥1.22b (flat on FY 2022). Net income: CN¥11.0m (up CN¥13.8m from FY 2022). Profit margin: 0.9% (up from net loss in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China.New Risk • Feb 07New major risk - Revenue and earnings growthEarnings have declined by 25% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.お知らせ • Dec 29Anshan Hifichem Co., Ltd. to Report Fiscal Year 2023 Results on Feb 29, 2024Anshan Hifichem Co., Ltd. announced that they will report fiscal year 2023 results on Feb 29, 2024New Risk • Dec 22New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.021 (vs CN¥0.009 loss in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.021 (up from CN¥0.009 loss in 3Q 2022). Revenue: CN¥317.7m (up 7.1% from 3Q 2022). Net income: CN¥7.96m (up CN¥10.6m from 3Q 2022). Profit margin: 2.5% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China.New Risk • Oct 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.お知らせ • Sep 30Anshan Hifichem Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023Anshan Hifichem Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CN¥0.007 (vs CN¥0.002 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.007 (up from CN¥0.002 in 2Q 2022). Revenue: CN¥308.0m (flat on 2Q 2022). Net income: CN¥2.96m (up 188% from 2Q 2022). Profit margin: 1.0% (up from 0.3% in 2Q 2022).Reported Earnings • Apr 26First quarter 2023 earnings released: CN¥0.04 loss per share (vs CN¥0.06 profit in 1Q 2022)First quarter 2023 results: CN¥0.04 loss per share (down from CN¥0.06 profit in 1Q 2022). Revenue: CN¥263.6m (down 18% from 1Q 2022). Net loss: CN¥14.8m (down 160% from profit in 1Q 2022).Board Change • Mar 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Anshan Hifichem は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測XSEC:300758 - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20261,53146-4094N/A12/31/20251,49561-9864N/A9/30/20251,53378-9749N/A6/30/20251,588110-7862N/A3/31/20251,61013418103N/A12/31/20241,56812558133N/A9/30/20241,48313532130N/A6/30/20241,38590-3686N/A3/31/20241,27747-9348N/A12/31/20231,21811-1642N/A9/30/20231,168-30-17243N/A6/30/20231,147-40-16356N/A3/31/20231,149-42-80122N/A1/1/20231,209-3-9992N/A9/30/20221,34353-40107N/A6/30/20221,37093-38118N/A3/31/20221,361157-63107N/A1/1/20221,347180-1161N/A9/30/20211,248192-25143N/A6/30/20211,193197-39119N/A3/31/20211,142187-26123N/A12/31/20201,008175-14193N/A9/30/2020877141-18184N/A6/30/2020774142-19562N/A3/31/2020724130-23815N/A12/31/2019695108N/A49N/A9/30/2019661120N/A47N/A6/30/2019664111N/A85N/A3/31/2019628100N/A87N/A12/31/2018611105N/A68N/A9/30/2018606115N/A63N/A6/30/2018583110N/A76N/A3/31/2018550101N/A48N/A12/31/2017553103N/A72N/A9/30/2017525100N/A61N/A6/30/201749896N/A51N/A3/31/201747086N/A62N/A12/31/201644276N/A73N/A9/30/201641960N/AN/AN/A6/30/201639644N/A29N/A3/31/201638341N/A30N/A12/31/201537039N/A32N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 300758の予測収益成長が 貯蓄率 ( 2.4% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 300758の収益がCN市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 300758の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 300758の収益がCN市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 300758の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 300758の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 02:16終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Anshan Hifichem Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Nai Di ZhaoEverbright Securities Co. Ltd.Wei LiuHaitong International Research Limited
お知らせ • Apr 24Anshan Hifichem Co., Ltd., Annual General Meeting, May 15, 2026Anshan Hifichem Co., Ltd., Annual General Meeting, May 15, 2026, at 13:00 China Standard Time. Location: No. 8, Yihao Road, Teng'ao Economic Development Zone, Haicheng, Anshan, Liaoning China
お知らせ • Mar 31Anshan Hifichem Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026Anshan Hifichem Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026
お知らせ • Dec 31Anshan Hifichem Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026Anshan Hifichem Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026
お知らせ • Sep 30Anshan Hifichem Co., Ltd. to Report Q3, 2025 Results on Oct 22, 2025Anshan Hifichem Co., Ltd. announced that they will report Q3, 2025 results on Oct 22, 2025
お知らせ • Jul 02Anshan Hifichem Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025Anshan Hifichem Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025
お知らせ • Apr 18Anshan Hifichem Co., Ltd., Annual General Meeting, May 09, 2025Anshan Hifichem Co., Ltd., Annual General Meeting, May 09, 2025, at 13:00 China Standard Time. Location: No. 8, Yihao Road, Teng'ao Economic Development Zone, Haicheng, Anshan, Liaoning China
お知らせ • Mar 31Anshan Hifichem Co., Ltd. to Report Q1, 2025 Results on Apr 18, 2025Anshan Hifichem Co., Ltd. announced that they will report Q1, 2025 results on Apr 18, 2025
お知らせ • Dec 31Anshan Hifichem Co., Ltd. to Report Fiscal Year 2024 Results on Apr 18, 2025Anshan Hifichem Co., Ltd. announced that they will report fiscal year 2024 results on Apr 18, 2025
Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.021 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.13 (up from CN¥0.021 in 3Q 2023). Revenue: CN¥415.5m (up 31% from 3Q 2023). Net income: CN¥53.0m (up CN¥45.1m from 3Q 2023). Profit margin: 13% (up from 2.5% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 31%After last week's 31% share price gain to CN¥13.06, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 35% over the past year.
New Risk • Sep 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.8% average weekly change).
お知らせ • Sep 30Anshan Hifichem Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024Anshan Hifichem Co., Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024
お知らせ • Sep 21Anshan Hifichem Co., Ltd. Announces 2024 Interim Profit Distribution Plan (A Shares),Payable September 26, 2024Anshan Hifichem Co., Ltd. announced 2024 interim profit distribution plan to be implemented (A shares):Cash dividend/10 shares (tax included): CNY0.50000000. Record date: 25 September 2024, Ex-date: 26 September 2024, Payment date: 26 September 2024.
New Risk • Sep 07New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.9% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
Reported Earnings • Aug 27Second quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.007 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.13 (up from CN¥0.007 in 2Q 2023). Revenue: CN¥416.2m (up 35% from 2Q 2023). Net income: CN¥45.6m (up CN¥42.6m from 2Q 2023). Profit margin: 11% (up from 1.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.
お知らせ • Jun 29Anshan Hifichem Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024Anshan Hifichem Co., Ltd. announced that they will report first half, 2024 results on Aug 27, 2024
Reported Earnings • Apr 16First quarter 2024 earnings released: EPS: CN¥0.05 (vs CN¥0.04 loss in 1Q 2023)First quarter 2024 results: EPS: CN¥0.05 (up from CN¥0.04 loss in 1Q 2023). Revenue: CN¥322.5m (up 22% from 1Q 2023). Net income: CN¥21.6m (up CN¥36.4m from 1Q 2023). Profit margin: 6.7% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China.
New Risk • Apr 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Large one-off items impacting financial results.
お知らせ • Mar 30Anshan Hifichem Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024Anshan Hifichem Co., Ltd. announced that they will report Q1, 2024 results on Apr 24, 2024
お知らせ • Feb 09Anshan Hifichem Co., Ltd., Annual General Meeting, Mar 01, 2024Anshan Hifichem Co., Ltd., Annual General Meeting, Mar 01, 2024, at 13:00 China Standard Time. Location: No. 8, Yihao Road, Teng'ao Economic Development Zone, Haicheng, Anshan, Liaoning China
New Risk • Feb 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Large one-off items impacting financial results.
Reported Earnings • Feb 07Full year 2023 earnings released: EPS: CN¥0.03 (vs CN¥0.01 loss in FY 2022)Full year 2023 results: EPS: CN¥0.03 (up from CN¥0.01 loss in FY 2022). Revenue: CN¥1.22b (flat on FY 2022). Net income: CN¥11.0m (up CN¥13.8m from FY 2022). Profit margin: 0.9% (up from net loss in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China.
New Risk • Feb 07New major risk - Revenue and earnings growthEarnings have declined by 25% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
お知らせ • Dec 29Anshan Hifichem Co., Ltd. to Report Fiscal Year 2023 Results on Feb 29, 2024Anshan Hifichem Co., Ltd. announced that they will report fiscal year 2023 results on Feb 29, 2024
New Risk • Dec 22New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.021 (vs CN¥0.009 loss in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.021 (up from CN¥0.009 loss in 3Q 2022). Revenue: CN¥317.7m (up 7.1% from 3Q 2022). Net income: CN¥7.96m (up CN¥10.6m from 3Q 2022). Profit margin: 2.5% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China.
New Risk • Oct 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
お知らせ • Sep 30Anshan Hifichem Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023Anshan Hifichem Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023
Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CN¥0.007 (vs CN¥0.002 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.007 (up from CN¥0.002 in 2Q 2022). Revenue: CN¥308.0m (flat on 2Q 2022). Net income: CN¥2.96m (up 188% from 2Q 2022). Profit margin: 1.0% (up from 0.3% in 2Q 2022).
Reported Earnings • Apr 26First quarter 2023 earnings released: CN¥0.04 loss per share (vs CN¥0.06 profit in 1Q 2022)First quarter 2023 results: CN¥0.04 loss per share (down from CN¥0.06 profit in 1Q 2022). Revenue: CN¥263.6m (down 18% from 1Q 2022). Net loss: CN¥14.8m (down 160% from profit in 1Q 2022).
Board Change • Mar 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.